UPenn study of CRISPR/Cas9 cell therapy in cancers doses first patients
NPR reported that the two patients, one with multiple myeloma and one with sarcoma, had received the gene-edited cell therapy as part of a Phase I trial.
NPR reported that the two patients, one with multiple myeloma and one with sarcoma, had received the gene-edited cell therapy as part of a Phase I trial.
A conversation with investor Gary Kurtzman.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.